Morin Chelsea M D, Ivey James W, Titosky Jordan T F, Suderman Jonathan D, Olfert Jason S, Vehring Reinhard, Finlay Warren H
Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta.
J Pharm Sci. 2014 Nov;103(11):3553-3559. doi: 10.1002/jps.24145. Epub 2014 Sep 22.
The performance of pressurized metered-dose inhalers (pMDIs) under a variety of temperature conditions was investigated. The effects of both inhaler temperature and ambient temperature were considered. The inhaler temperature ranged from -13.0°C to 41.7°C and the ambient temperature ranged from -12.0°C to 41.7°C. The in vitro lung dose was measured for four widely available pMDIs: Airomir(TM) , QVAR(TM) , Symbicort(®) , and Ventolin(®) . The in vitro lung dose through an Alberta Idealized Throat was measured by gravimetric assay, which was verified by UV spectroscopic assay. A decrease in the in vitro lung dose was observed for all evaluated pMDIs when ambient temperature and device temperature were simultaneously reduced, decreasing on average by 70% at the coldest temperatures, whereas increasing on average by 25% at the elevated temperature condition. In vitro lung dose is strongly dependent on both inhaler temperature and ambient temperature with the tested pMDIs.
研究了加压定量吸入器（pMDIs）在各种温度条件下的性能。考虑了吸入器温度和环境温度的影响。吸入器温度范围为-13.0°C至41.7°C，环境温度范围为-12.0°C至41.7°C。对四种广泛使用的pMDIs进行了体外肺部剂量测量：Airomir(TM)、QVAR(TM)、Symbicort(®)和Ventolin(®)。通过重量分析法测量通过艾伯塔理想化咽喉的体外肺部剂量，并通过紫外光谱分析法进行验证。当环境温度和装置温度同时降低时，所有评估的pMDIs的体外肺部剂量均出现下降，在最冷温度下平均下降70%，而在高温条件下平均增加25%。对于所测试的pMDIs，体外肺部剂量强烈依赖于吸入器温度和环境温度。
